102 related articles for article (PubMed ID: 16290311)
1. Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis.
Tanaka S; Wands JR; Arii S
J Hepatol; 2006 Jan; 44(1):233-5. PubMed ID: 16290311
[No Abstract] [Full Text] [Related]
2. [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice].
Zuo CH; Li ZR; Zhou X; Ouyang YZ; Zhou ZY; Zeng L
Ai Zheng; 2006 Apr; 25(4):414-20. PubMed ID: 16613672
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line.
Roy KR; Reddy GV; Maitreyi L; Agarwal S; Achari C; Vali S; Reddanna P
Cancer Chemother Pharmacol; 2010 Apr; 65(5):903-11. PubMed ID: 19685055
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Li S; Tong Q; Zhang W; Wang Q; Chen Z; Wu Q
Cancer Invest; 2008 May; 26(4):333-7. PubMed ID: 18443952
[TBL] [Abstract][Full Text] [Related]
5. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
6. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
7. [Molecular structure and abnormal expression of angiopoietin-2 and antiangiogenic targeting therapy of hepatocelluar carcinoma].
GU WJ; YAO DF
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):398-400. PubMed ID: 19497214
[No Abstract] [Full Text] [Related]
8. Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma.
Kuboki S; Shimizu H; Mitsuhashi N; Kusashio K; Kimura F; Yoshidome H; Ohtsuka M; Kato A; Yoshitomi H; Miyazaki M
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e157-64. PubMed ID: 17931370
[TBL] [Abstract][Full Text] [Related]
9. [Effects of COX-2 gene silencing by shRNA on biological characteristics of human hepatocellular carcinoma cell line HepG2].
Xu KS; Wang HF; Qian W; Wang BH
Ai Zheng; 2007 Jan; 26(1):32-7. PubMed ID: 17222364
[TBL] [Abstract][Full Text] [Related]
10. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein.
Park IY; Sohn BH; Yu E; Suh DJ; Chung YH; Lee JH; Surzycki SJ; Lee YI
Gastroenterology; 2007 Apr; 132(4):1476-94. PubMed ID: 17408664
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Kern MA; Haugg AM; Koch AF; Schilling T; Breuhahn K; Walczak H; Fleischer B; Trautwein C; Michalski C; Schulze-Bergkamen H; Friess H; Stremmel W; Krammer PH; Schirmacher P; Müller M
Cancer Res; 2006 Jul; 66(14):7059-66. PubMed ID: 16849551
[TBL] [Abstract][Full Text] [Related]
12. Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro-angiogenic and prometastatic factors in murine liver fibrosis.
Kornek M; Raskopf E; Tolba R; Becker U; Klöckner M; Sauerbruch T; Schmitz V
Liver Int; 2008 Apr; 28(4):509-18. PubMed ID: 18339078
[TBL] [Abstract][Full Text] [Related]
13. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.
Lim SO; Gu JM; Kim MS; Kim HS; Park YN; Park CK; Cho JW; Park YM; Jung G
Gastroenterology; 2008 Dec; 135(6):2128-40, 2140.e1-8. PubMed ID: 18801366
[TBL] [Abstract][Full Text] [Related]
15. Biological effect of ectopic expression of angiopoietin-1 and -2 in hepatocellular carcinoma cell line.
Peng L; Sun J; Wang WD; Jian ZX; Ou JR
Hepatobiliary Pancreat Dis Int; 2003 Feb; 2(1):94-7. PubMed ID: 14607656
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma.
Lv Z; Zhang M; Bi J; Xu F; Hu S; Wen J
Am J Clin Pathol; 2006 May; 125(5):740-6. PubMed ID: 16707376
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.
Nagahara T; Okano J; Murawaki Y
Oncol Rep; 2007 Nov; 18(5):1281-90. PubMed ID: 17914586
[TBL] [Abstract][Full Text] [Related]
19. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis.
Peng G; Dixon DA; Muga SJ; Smith TJ; Wargovich MJ
Mol Carcinog; 2006 May; 45(5):309-19. PubMed ID: 16508969
[TBL] [Abstract][Full Text] [Related]
20. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis.
Zhao QT; Yue SQ; Cui Z; Wang Q; Cui X; Zhai HH; Zhang LH; Dou KF
Life Sci; 2007 Jan; 80(5):484-92. PubMed ID: 17097688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
